Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades.

The launch of generic abiraterone means next generation anti-androgens in development will likely be pushed into earlier settings than the late-stage disease Johnson & Johnson’s branded Zytiga abiraterone has traditionally treated. ...